Indication: DLBCL
Title: Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Drug: selinexor

Please visit clinicaltrials.gov for more information about this study.

Rights

Expected to start in 2020.

Phase IPhase IIPhase III
Phase I
Phase II
Phase III